VTGN VTGN

Q: What is the current share price of VTGN?

As of 2026-08-05 17:25 PDT, VTGN trades at $0.30 on NASDAQ/NYSE. Its 52-week range is $0.23 to $4.90.

Q: What is the market capitalisation of VTGN?

VTGN has a market capitalisation of $11.89M on NASDAQ/NYSE.

Q: What is the P/E ratio of VTGN?

VTGN trades at a trailing price-to-earnings (P/E) ratio of -0.16. Its price-to-book (P/B) ratio is 0.33.

Q: Is VTGN a good stock to buy?

This page provides a data-driven analysis of VTGN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Company Profile ↓

$0.30

-89.83% 1Y

Mkt Cap$11.89M

P/E-0.16

P/B0.33

52W High$4.90

52W Low$0.23

Book Value$0.90

EPS (TTM)$-1.83

Company Overview

VTGN (VTGN) is a publicly traded company listed on with a market capitalization of $11.89M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Recent Developments

Mar 2026 Revenue of $1.27M (+161.1% YoY); net profit $-69.69M.
Trailing 12 Months Year-on-year growth — revenue +161.1%.
5-Year Trend Long-term compounding — revenue CAGR -4.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-4.36%
1 Year:	161.11%

Stock Price Performance

1 Year:	-89.83%
6 Months:	-45.00%
3 Months:	-50.50%
1 Month:	+23.75%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 1% of range

$0.23 $4.90

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)48.37 · Neutral

Price Performance

1M+23.75%

3M-50.50%

6M-45.00%

1Y-89.83%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Revenue declined at -4.4% CAGR over 5 years.
Trading 93.9% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.16

Industry PE

Forward P/E

PEG Ratio

Book Value

$0.90

Price to Book

0.33

P/S

EV/EBITDA

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-4.36%

Profit 5Y

Revenue (YoY)

161.11%

Earnings (YoY)

Profitability & Returns

ROCE

ROE

ROA

Profit Margin

Op Margin

Gross Margin

EPS (Latest Qtr)

$-0.45

EPS (TTM)

$-1.83

Balance Sheet & Liquidity

Debt/Equity

2.94

Quick Ratio

Current Ratio

3.67

Debt

$1.04M

Total Assets

$48.56M

Current Assets

$46.94M

Working Capital

$34.15M

Ownership

Promoter Holding

0.29%

Chg in Prom Hold

FII / Inst Holding

40.89%

Chg in FII Hold

Financial Snapshot

Enterprise Value

Total Revenue (TTM)

$1.27M

EBITDA

$-71.39M

Free Cash Flow

$-66.59M

Operating Cash Flow

$-66.44M

Shares Outstanding

39.62M

Gross Margin

Payout Ratio

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	0	0	1.25M	0	-	-	0	-	-	-	-	-	0	0	0	0	0	334.00K	314.00K	442.00K	354.00K	358.00K	358.00K	39.00K	310.00K	-893.00K	180.00K	176.00K	-	-	-	-	-	-	-15.00K	244.00K	258.00K	303.00K	465.00K
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.48M	16.05M	20.31M	19.85M	17.18M
Operating Income	-8.50M	-1.96M	-3.10M	-2.64M	-2.55M	-2.26M	-4.99M	-2.87M	-4.08M	-4.21M	-7.43M	-7.19M	-5.72M	-6.22M	-5.35M	-5.96M	-3.26M	-3.12M	-3.29M	-5.30M	-6.22M	-7.75M	-12.80M	-10.54M	-16.69M	-19.77M	-17.49M	-9.77M	-12.24M	-7.00M	-6.78M	-7.88M	-12.13M	-14.23M	-	-14.49M	-15.80M	-20.05M	-19.55M	-16.72M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14.33M	-15.63M	-19.87M	-19.36M	-16.53M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-13.63M	-15.10M	-19.42M	-18.90M	-16.27M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	7.00K
Net Income	-8.50M	-1.97M	-3.10M	-2.64M	-2.55M	-2.27M	-5.00M	-3.00M	-4.08M	-4.21M	-7.43M	-7.22M	-5.72M	-6.21M	-5.34M	-5.96M	-3.27M	-3.13M	-3.30M	-5.30M	-6.21M	-7.75M	-12.79M	-10.53M	-16.69M	-19.78M	-17.48M	-9.76M	-12.23M	-6.90M	-6.59M	-6.35M	-10.73M	-12.96M	-	-13.63M	-15.10M	-19.42M	-18.90M	-16.27M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.94	-0.66	-0.22	-0.35	-0.42	-0.46	-	-0.47	-0.54	-0.45	-
R&D Expense	1.10M	826.00K	1.61M	1.61M	1.16M	1.10M	2.43M	1.60M	2.64M	2.74M	5.26M	5.33M	3.76M	4.31M	4.21M	3.02M	1.84M	15.00K	2.36M	3.50M	4.89M	5.46M	9.94M	7.78M	12.23M	15.29M	12.89M	6.85M	9.34M	4.20M	3.85M	4.54M	7.65M	10.21M	11.30M	-	11.68M	15.91M	14.22M	-

Profit & Loss (Annual)

Figures in USD.

Metric	Mar 1999	Mar 2000	Mar 2001	Mar 2002	Mar 2003	Mar 2004	Mar 2005	Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	2.07M	1.34M	200.40K	-	-	0	1.25M	0	-	0	1.09M	-	-227.00K	1.06M	486.00K	1.27M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	59.04M	34.09M	56.46M	73.39M
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-6.56M	-9.04M	-6.79M	-5.03M	-6.78M	-17.85M	-10.25M	-14.20M	-24.56M	-20.80M	-17.93M	-	-59.27M	-33.02M	-55.97M	-72.13M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-58.74M	-32.45M	-55.34M	-71.39M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	23.00K	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-59.24M	-29.36M	-51.41M	-69.68M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00K	4.00K	7.00K	7.00K
Net Income	-230.90K	-700.00K	-1.81M	-2.11M	-502.60K	-8.76M	-1.08M	-1.77M	-2.00M	-5.45M	-4.70M	-4.12M	-9.48M	-12.21M	-12.89M	-2.97M	-13.89M	-47.22M	-10.26M	-14.35M	-24.59M	-20.77M	-17.93M	-	-59.25M	-29.36M	-51.42M	-69.69M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-1.81	-0.83	-1.27	-3.81	-10.61	-29.08	-	-	-	-	-	-	-8.51	-1.52	-1.67	-1.83
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	3.68M	5.39M	3.43M	2.48M	2.43M	3.93M	5.20M	7.76M	17.10M	13.37M	11.93M	35.41M	44.38M	20.02M	39.38M	54.97M

Balance Sheet (Annual)

Figures in USD.

Metric	Mar 1999	Mar 2000	Mar 2001	Mar 2002	Mar 2003	Mar 2004	Mar 2005	Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	-	-	-	-	-	-	-	-	-	-	-	323.60K	341.60K	881.50K	263.70K	269.70K	989.80K	3.71M	11.28M	14.01M	5.77M	108.28M	-	21.09M	123.65M	84.34M	48.56M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.51M	120.67M	82.08M	46.94M
Cash & Equivalents	-	-	-	-	-	-	-	-	-	-	-	201.00K	139.30K	81.00K	638.10K	-	70.00K	428.50K	2.92M	10.38M	13.10M	1.36M	103.11M	-	16.64M	119.17M	67.13M	30.79M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.75M	802.70K	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	18.67M	6.05M	13.44M	13.06M	20.81M	3.97M	3.10M	4.36M	6.94M	11.50M	16.30M	-	9.01M	9.37M	13.95M	13.04M
Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	10.83M	3.18M	2.41M	5.21M	17.39M	1.79M	1.37M	1.46M	2.80M	27.71M	4.19M	-	4.57M	5.12M	12.61M	12.79M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.06M	1.51M	58.80K	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.71M	2.12M	1.51M	1.04M
Total Equity	-225.50K	-844.10K	-2.51M	-4.58M	-4.95M	-13.69M	-14.74M	-16.50M	-17.45M	-22.17M	-26.68M	-26.34M	-32.88M	-5.71M	-12.56M	-12.80M	-20.54M	-2.98M	615.80K	6.92M	7.08M	-5.73M	91.98M	-	12.08M	114.29M	70.39M	35.52M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.32M	27.03M	29.00M	39.62M

Cash Flows (Annual)

Figures in USD.

Metric	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-841.30K	-3.57M	-3.46M	-2.13M	-2.77M	-	-	-9.06M	-14.53M	-15.76M	-12.07M	-	-49.72M	-25.81M	-42.10M	-66.44M
Investing Cash Flow	-57.80K	-32.40K	-135.40K	9.60K	-	-26.30K	-239.10K	-1.60K	-174.00K	0	-275.40K	-	-740.00K	-61.00K	-13.15M	-877.00K
Financing Cash Flow	837.40K	3.54M	4.16M	1.50M	2.84M	-	-	16.52M	17.42M	4.01M	114.10M	-	-1.04M	128.40M	3.21M	30.97M
Capital Expenditure	-	-	-	-	-	-26.30K	-239.10K	-1.60K	-174.00K	-0	-275.40K	-	-212.00K	-61.00K	-191.00K	-151.00K
Free Cash Flow	-	-	-	-	-	-	-	-9.06M	-14.70M	-15.76M	-12.35M	-	-49.93M	-25.87M	-42.29M	-66.59M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-51.50M	102.53M	-52.03M	-36.34M

Ratios (Annual)

Figures in %.

Metric	Mar 1999	Mar 2000	Mar 2001	Mar 2002	Mar 2003	Mar 2004	Mar 2005	Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-317.0%	-673.8%	-3,389.8%	-	-	-	-819.9%	-	-	-	-1,646.1%	-	26,109.3%	-3,103.5%	-11,517.1%	-5,683.7%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-457.9%	-909.7%	-6,430.5%	-	-	-	-820.4%	-	-	-	-1,646.1%	-	26,100.4%	-2,759.6%	-10,579.8%	-5,491.3%
ROE %	102.4%	82.9%	72.0%	46.1%	10.2%	64.0%	7.3%	10.7%	11.5%	24.6%	17.6%	15.7%	28.8%	214.0%	102.6%	23.2%	67.6%	1,586.1%	-1,665.4%	-207.4%	-347.5%	362.6%	-19.5%	-	-490.5%	-25.7%	-73.0%	-196.2%
ROCE %	-	-	-	-	-	-	-	-	-	-	-	-	62.5%	318.3%	443.2%	101.8%	39.6%	2,217.7%	-437.1%	-144.6%	-219.0%	94.8%	-17.2%	-	-358.9%	-27.9%	-78.0%	-201.6%

Shareholding Pattern

Insiders

0.29%

Institutions

40.89%

Public Float

41.01%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VTGN

Google News Wed, 15 Jul 2026

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPWXVhWXVUMExaQ205SGU1QUdEdkFxZjVlb3dLSzFmWXFqRnJHWS1iRVBHUXlpMElUYXRGR3RRN21aX19UUVo3NEF1a0VMQWFBamhWVk1DQXlxQ0x4ajlPSnRDdFJBeHpFd1MyVXBjZlFUT2JjYVNoNkFMcHZoMnZ3bzh4MEFOVERFTGd2bG…

Google News Fri, 31 Jul 2026

Vistagen adds board director with nearly three decades in neuroscience drug development - Stock Titan

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNLXFkamdtYjFwRUVud2I3VkxpRG5YTXdfRHBiUlNDb0JRMVNQZzZDa3laOEZ5aWVZTzZDVWlQN0RhSlRTM3dOUTA5OGJkRmRJZmRlYWVKdnFmSmQzN3ByeVc1ZVhtUlFxcVNwMzgtZWJ4a0RkRmJuMU1Oa1IzMmpSeU1Tbm1JNTVIY0VwY0…

Google News ue, 04 Aug 2026

These stocks are making the most noise in today's session. - ChartMill

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQTnJ3Wm9tMmRsVGtXUlo2WjdxWUFmSXdROGxRU3FsODMyZGVUaHo2YnNuWkFTNGVRU1lia3ZoMTAtT25DYzNLUHE3MVAxSTBxaXdFMVFLd05aeDJfdjljdkxySGxXdnViNVJ6alhJTVRNSnFoZll6X2JRNGxRMFlHbzlGX281UlNvSmdPWl…

Google News hu, 25 Jun 2026

VTGN Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE82aU0zWTQ1QVMwX3FYeVRPUldOX0d0eFVFaGljUkREdHJkMUVjeUNlM2I4dmRHNHJjN040R2dQVEF2Z3hfam14VnZCN0NSSEtKaC1HeUNTSVNxUU1hbURpMlRkanYwMktMMGFrM1dZRVNod1lJaVZXODJ3?oc=5" target="_blank">VTG…

Google News Mon, 27 Apr 2026

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop - Schubert Jonckheer & Kolbe

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE5IMlg1RGl0WjdTMF94MjFhZ2lkS0x0M1FyUTliTjBZbkNuNEtuOFF6ZmdqTno2Ty1vZkxyMGwwV3FfOU1pOUlBM1JoUndaV1U3TkhvZ2N3Yk1SVHc3?oc=5" target="_blank">Vistagen Therapeutics, Inc. (NASDAQ: VTGN) …

Google News Mon, 15 Jun 2026

VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOcGpPZXNfNFV3Q2VXNlBNSHc0NEJZVUJ2bVBCNy1PczZYZzRjS2xsdUdiQU9IaFVyT2VnUlFrYnVRdmJjREtpaXdZc2ZfLUYtN3ZuWE1LeFJRU0lBSm1oTjZvdFdaUF9WV0ZqQnlPcGRoTDFqSzhvUlVRYVNFTmJfT2o0ckhxWVBNWmE5Rm…

VTGN — Frequently Asked Questions

What is the current share price of VTGN?

As of 2026-08-05 17:25 PDT, VTGN trades at $0.30 on NASDAQ/NYSE. Its 52-week range is $0.23 to $4.90.

What is the market capitalisation of VTGN?

VTGN has a market capitalisation of $11.89M on NASDAQ/NYSE.

What is the P/E ratio of VTGN?

VTGN trades at a trailing price-to-earnings (P/E) ratio of -0.16. Its price-to-book (P/B) ratio is 0.33.

Is VTGN a good stock to buy?

This page provides a data-driven analysis of VTGN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

VTGN VTGN

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Analyst View

Latest News

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? - Yahoo Finance

Vistagen adds board director with nearly three decades in neuroscience drug development - Stock Titan

These stocks are making the most noise in today's session. - ChartMill

VTGN Forecast — Price Target — Prediction for 2027 - TradingView

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop - Schubert Jonckheer & Kolbe

VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings - Quiver Quantitative

VTGN — Frequently Asked Questions

What is the current share price of VTGN?

What is the market capitalisation of VTGN?

What is the P/E ratio of VTGN?

Is VTGN a good stock to buy?

Explore More